CVS/$CVS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CVS
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It operates a top-tier health insurer (acquired through Aetna) through which it serves about 27 million medical members. The acquisition of Oak Street Health adds primary care services to the mix, which could have significant synergies with all existing business lines.
Ticker
$CVS
Sector
Primary listing
NYSE
Employees
259,500
Headquarters
Website
CVS Metrics
BasicAdvanced
$102B
22.47
$3.59
0.62
$2.66
3.30%
Price and volume
Market cap
$102B
Beta
0.62
52-week high
$81.93
52-week low
$43.56
Average daily volume
7.7M
Dividend rate
$2.66
Financial strength
Current ratio
0.803
Quick ratio
0.582
Long term debt to equity
92.35
Total debt to equity
106.67
Dividend payout ratio (TTM)
74.62%
Interest coverage (TTM)
3.09%
Profitability
EBITDA (TTM)
14,073
Gross margin (TTM)
13.30%
Net profit margin (TTM)
1.18%
Operating margin (TTM)
2.46%
Effective tax rate (TTM)
30.89%
Revenue per employee (TTM)
$1,480,000
Management effectiveness
Return on assets (TTM)
2.31%
Return on equity (TTM)
5.88%
Valuation
Price to earnings (TTM)
22.469
Price to revenue (TTM)
0.265
Price to book
1.32
Price to tangible book (TTM)
-2.55
Price to free cash flow (TTM)
21.298
Free cash flow yield (TTM)
4.70%
Free cash flow per share (TTM)
3.788
Dividend yield (TTM)
3.30%
Forward dividend yield
3.30%
Growth
Revenue change (TTM)
6.21%
Earnings per share change (TTM)
-36.25%
3-year revenue growth (CAGR)
7.78%
10-year revenue growth (CAGR)
10.19%
3-year earnings per share growth (CAGR)
-16.78%
10-year earnings per share growth (CAGR)
-1.41%
3-year dividend per share growth (CAGR)
8.20%
10-year dividend per share growth (CAGR)
7.84%
What the Analysts think about CVS
Analyst ratings (Buy, Hold, Sell) for CVS stock.
Bulls say / Bears say
CVS Health’s Aetna unit reported a medical loss ratio of 89.9% in Q2 2025, beating analyst projections of 91.16% and driving a full-year EPS guidance raise to $6.30–$6.40 per share from $6.00–$6.20 (Reuters).
The Pharmacy & Consumer Wellness segment delivered 12.5% revenue growth to $33.58 billion in Q2 2025, bolstered by favorable drug mix and increased prescription volumes, while the Caremark PBM unit saw 10.2% revenue growth, highlighting robust demand across retail and PBM operations (Reuters).
Oak Street Health’s planned expansion to over 300 clinics by 2026 is projected to generate more than $2 billion in adjusted EBITDA and yield over $500 million in annual synergies, underscoring the long-term growth potential of CVS’s primary care integration strategy (Reuters Breakingviews).
The Healthcare Services segment, which includes CVS’s Oak Street Health primary care business, saw adjusted operating income decline by 17.6% year-over-year in Q2 2025 due to elevated medical costs and mix pressures, reflecting integration challenges and persistent cost headwinds (Healthcare Dive).
CVS recorded a $471 million premium deficiency reserve in Q2 2025 for its Group Medicare Advantage plans and experienced a sequential membership decline of 358,000, signaling ongoing utilization pressures and potential profitability risks in its insurance operations (SEC Filing).
Despite top-line growth, the PBM segment’s adjusted operating income fell over 17% year-over-year in Q2 2025, driven by client price concessions and competitive pricing pressures that weigh on Caremark’s profit margins (Associated Press).
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2025.
CVS Financial Performance
Revenues and expenses
CVS Earnings Performance
Company profitability
CVS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for CVS stock?
CVS (CVS) has a market cap of $102B as of October 16, 2025.
What is the P/E ratio for CVS stock?
The price to earnings (P/E) ratio for CVS (CVS) stock is 22.47 as of October 16, 2025.
Does CVS stock pay dividends?
Yes, the CVS (CVS) stock pays dividends to shareholders. As of October 16, 2025, the dividend rate is $2.66 and the yield is 3.3%. CVS has a payout ratio of 74.62% on a trailing twelve-month basis.
When is the next CVS dividend payment date?
The next CVS (CVS) dividend payment is scheduled for November 03, 2025.
What is the beta indicator for CVS?
CVS (CVS) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.